Biomedical Research Education & Training
Faculty Member

Hande, Kenneth R., M.D.
Professor of Medicine
Professor of Pharmacology

Lab Url: N/A

Phone Number: 615-322-4967

Email Address: kenneth.r.hande@vanderbilt.edu

Hande, Kenneth's picture
Academic history
A.B., Princeton
M.D., Johns Hopkins

Office Address   Mailing Address

777 PRB 37232-6307


Publications
Shi, C, Gonzalez, RS, Zhao, Z, Koyama, T, Cornish, TC, Hande, KR, Walker, R, Sandler, M, Berlin, J, Liu, EH. Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. Am J Clin Pathol, 143(3), 398-404, 2015

Cates, JM, Black, J, Wolfe, CC, Shinohara, ET, Holt, GE, Keedy, VL, Hande, KR, Homlar, KC, Halpern, JL, Schwartz, HS, Troutman, A, Coffin, CM. Morphologic and immunophenotypic analysis of desmoid-type fibromatosis after radiation therapy. Hum Pathol, 43(9), 1418-24, 2012

Cates, JM, Black, JO, Itani, DM, Fasig, JH, Keedy, VL, Hande, KR, Whited, BW, Homlar, KC, Halpern, JL, Holt, GE, Schwartz, HS, Coffin, CM. Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases. Hum Pathol, 43(10), 1711-8, 2012

Kallen, ME, Sanders, ME, Gonzalez, AL, Black, JO, Keedy, VL, Hande, KR, Homlar, KC, Halpern, JL, Holt, GE, Schwartz, HS, Coffin, CM, Cates, JM. Nuclear p63 expression in osteoblastic tumors. Tumour Biol, 33(5), 1639-44, 2012

Mignemi, NA, Itani, DM, Fasig, JH, Keedy, VL, Hande, KR, Whited, BW, Homlar, KC, Correa, H, Coffin, CM, Black, JO, Yi, Y, Halpern, JL, Holt, GE, Schwartz, HS, Schoenecker, JG, Cates, JM. Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-??, COX2 and sex steroid receptors. Cancer Sci, 103(12), 2173-80, 2012

Hande, KR, Hagey, A, Berlin, J, Cai, Y, Meek, K, Kobayashi, H, Lockhart, AC, Medina, D, Sosman, J, Gordon, GB, Rothenberg, ML. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res, 12(9), 2834-40, 2006

Lockhart, AC, Cropp, GF, Berlin, JD, Donnelly, E, Schumaker, RD, Schaaf, LJ, Hande, KR, Fleischer, AC, Hannah, AL, Rothenberg, ML. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Am J Clin Oncol, 29(2), 109-15, 2006

Martincic, D, Hande, KR. Topoisomerase II inhibitors. Cancer Chemother Biol Response Modif, 22, 101-21, 2005

Hande, Kenneth R, Collier, Mary, Paradiso, Linda, Stuart-Smith, Jill, Dixon, Mary, Clendeninn, Neil, Yeun, Geoff, Alberti, Donna, Binger, Kim, Wilding, George. Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clin Cancer Res, 10(3), 909-15, 2004

Lockhart, A Craig, Howard, Martin, Hande, Kenneth R, Roth, Bruce J, Berlin, Jordan D, Vreeland, Franzanne, Campbell, Angela, Fontana, Erminia, Fiorentini, Francesca, Fowst, Camilla, Paty, Victoria A, Lankford, Odessa, Rothenberg, Mace L. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin Cancer Res, 10(2), 468-75, 2004

Hande, KR. Topoisomerase II inhibitors. Cancer Chemother Biol Response Modif, 21, 103-25, 2003

Clapp JM and Hande KR. Topoisomerase II inhibitors. In Cancer Chemotherapy and Biological Response Modifiers, Annual 19. 125-149, 2002.

Hande KR. Purine Antimetabolites. In Encyclopedia of Cancer, 2nd Edition. JR Bertino ed. Academic Press, Amsterdam, 515-525, 2002.

Clapp, JaNae M, Hande, Kenneth R. Topoisomerase II inhibitors. Cancer Chemother Biol Response Modif, 20, 125-49, 2002

44. Hande KR. Purine Antimetabolites. In Cancer Chemotherapy and Biotherapy: Principles and Practice, 3rd edition. BA Chabner and DL Longo, eds. Lippincott Williams & Wilkins, Philadelphia, 295-314, 2001.

Dowell JE, Garrett AM, Shyr Y, Johnson, DA, Hande KR. A randomized Phase II trial in patients with carcinoma of unknown primary, Cancer 91:592-596, 2001.

Toonen TR, Hande KR. Topoisomerase II inhibitors. In Cancer Chemotherapy and Biological Response Modifiers, Annual 19. 129-147, 2001.

Choy, H, DeVore, R F, Hande, K R, Porter, L L, Rosenblatt, P A, Slovis, B, Laporte, K, Shyr, Y, Johnson, D H, , . Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. Lung Cancer, 34(3), 441-9, 2001

Dowell, J E, Garrett, A M, Shyr, Y, Johnson, D H, Hande, K R. A randomized Phase II trial in patients with carcinoma of an unknown primary site. Cancer, 91(3), 592-7, 2001

Toonen, T R, Hande, K R. Topoisomerase II inhibitors. Cancer Chemother Biol Response Modif, 19, 129-47, 2001

Choy H, DeVore RF, Hande KR et al. A Phase I outpatient trial of weekly Docetaxel and concurrent radiation therapy for stage III unresectable non-small cell lung cancer: A Vanderbilt Cancer Center Affiliate Network trial. Clinical Lung Cancer 1:27-31, 2000.

Choy H, DeVore RF, Hande KR, et al. A Phase II study of paclitaxel, carboplatin and hyperfractionated radiation therapy for locally inoperable non-small cell lung cancer. Int J Rad Onc Biol Phys 47:931-937, 2000.

Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD, Roberts JR, Carbone DP. Chromosome 19 translocation, overexpression, of Notch 3 and human lung cancer. J Natl Cancer Inst. 92:1355-1357, 2000.

Hande KR. Chemotherapy In Lung Cancer: Principles and Practice. H Pass, J Mitchell, D Johnson, A Turrisi and J Minna eds. Lippincott Williams & Wilkins, Philadelphia, Pa, pp 270-283, 2000.

Nicholson BP, Paul DM, Hande KR, Shyr Y, Meshad M,Cohen A, Johnson DH. Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. Clin Breast Cancer 1:136-143, 2000.

Choy, H, Chakravarthy, A, Devore, R F, Jagasia, M, Hande, K R, Roberts, J R, Johnson, D H, Yunus, F. Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC. Oncology (Huntingt), 14(7 Suppl 5), 43-6, 2000

Choy, H, De Vore, R F, Hande, K R, Porter, L L, Rosenblatt, P A, Slovis, B, Laporte, K, Shyr, Y, Johnson, D H. A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Clin Lung Cancer, 1 Suppl 1, S27-31, 2000

Choy, H, Devore, R F, Hande, K R, Porter, L L, Rosenblatt, P, Yunus, F, Schlabach, L, Smith, C, Shyr, Y, Johnson, D H. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys, 47(4), 931-7, 2000

Dang, T P, Gazdar, A F, Virmani, A K, Sepetavec, T, Hande, K R, Minna, J D, Roberts, J R, Carbone, D P. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst, 92(16), 1355-7, 2000

Nicholson, B P, Paul, D M, Hande, K R, Shyr, Y, Meshad, M, Cohen, A, Johnson, D H. Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. Clin Breast Cancer, 1(2), 136-43; discussion 144, 2000

Grunberg SM, Crowley J, Hande KR, et al. Treatment of poor prognosis, extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide?a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemother Pharmacol 44:461-468, 1999.

Hande K, Messenger M, Wagner J, Krozely M, and Kaul S. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Cancer Clin Res 5:2742-2747, 1999.

Hande KR. Principles and Pharmacology of Chemotherapy in Wintrobe?s Clinical Hematology. Lee GR, Foester J, Lukens J, Paraskeves F, Greer JP, and Rogers GM eds. Williams & Wilkins, Baltimore, pp 2076-2101, 1999.

Rothenberg ML, Nelson AR, and Hande KR. Matrix metalloproteinase inhibitors. Stem Cells 17:237-240, 1999.

Rothenberg, M L, Nelson, A R, Hande, K R. New drugs on the horizon: matrix metalloproteinase inhibitors. Stem Cells, 17(4), 237-40, 1999

Goren MP, Anthony LB, Hande KR, et al. Pharmacokinetics of an intravenous?oral vs. intravenous MESNA regimen in lung cancer patients receiving ifosfamide. J Clin Oncol 16:616-621, 1998.

Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochemica et Biophysica Acta 1400:173-184, 1998.

Hande KR.Etoposide:Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34:1514-1521,1998.

Rothenberg ML, Nelson AR, and Hande KR. New drugs on the horizon: matrix metalloproteinase inhibitors. The Oncologist 3:271-274, 1998.

Hande, K R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer, 34(10), 1514-21, 1998

Hande, K R. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta, 1400(1-3), 173-84, 1998

Rothenberg, , Nelson, , Hande, . New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors. Oncologist, 3(4), 271-274, 1998

Choy, H, DeVore, R F, Hande, K R, Porter, L L, Rosenblatt, P, Yunus, F, Schlabach, L, Smith, C, Shyr, Y, LaPorte, K, Johnson, D H. Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. Semin Oncol, 24(4 Suppl 12), S12-21-S12-26, 1997

Johnson, D H, Paul, D, Hande, K R. Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. Semin Oncol, 24(1 Suppl 3), S22-5, 1997

Nicholson, B, Paul, D, Shyr, Y, Garrett, M, Hande, K R, Johnson, D H. Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial. Semin Oncol, 24(4 Suppl 11), S11-20-S11-23, 1997

Deegan PM, Basinger MA, Jones MM, and Hande KR. Prevention of cisplatin nephrotoxicity exogenous atrial naturetic peptide. Toxicology 106:159-166, 1996.

Hande KR. The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Stem Cells14:18-24, 1996.

Johnson DH, Paul DP, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M, and DeVore RF. Paclitaxel plus carboplatin in advanced non-small cell lung cancer. A Phase II trial. J Clin Oncol 14:2054-2060, 1996.

Deegan, P M, Basinger, M A, Jones, M M, Hande, K R. Prevention of cisplatin nephrotoxicity by exogenous atrial natriuretic peptide. Toxicology, 106(1-3), 159-66, 1996

Hande, . The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example. Oncologist, 1(4), 234-239, 1996

Hande, K R. The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Stem Cells, 14(1), 18-24, 1996

Johnson, D H, Paul, D M, Hande, K R, DeVore, R. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46). Semin Oncol, 23(6 Suppl 16), 42-6, 1996

Johnson, D H, Paul, D M, Hande, K R, Shyr, Y, Blanke, C, Murphy, B, Lewis, M, De Vore, R F. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol, 14(7), 2054-60, 1996

Anthony LA, Boeve TJ, and Hande KR. Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes. Cancer Chemother Pharmacol 36:125-128, 1995.

Deegan PM, Nolan C, Ryan MP, Basinger MA, Jones MM, and Hande KR. The role of the renin-angiotensin system in cisplatin toxicity. Renal Failure 17:665-674, 1995.

Deegan PM, Ryan MP, Bassinger MA, Jones MM, and Hande KR. Protection from cisplatin nephrotoxicity by A68828, an atrial naturetic peptide. Renal Failure 17:117-123, 1995.

Thompson DS, Greco FA, Miller AA, Srinivas NR, Igwemezie LN, Hainsworth JD, Schacter LP, Kaul S, Babhaiya RH, Garrow GC, and Hande KR. A Phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days. Clin Pharmacol Ther 57:499-507, 1995.

Anthony, L B, Boeve, T J, Hande, K R. Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes. Cancer Chemother Pharmacol, 36(2), 125-8, 1995

Deegan, P M, Nolan, C, Ryan, M P, Basinger, M A, Jones, M M, Hande, K R. The role of the renin-angiotensin system in cisplatin nephrotoxicity. Ren Fail, 17(6), 665-74, 1995

Deegan, P M, Ryan, M P, Basinger, M A, Jones, M M, Hande, K R. Protection from cisplatin nephrotoxicity by A68828, an atrial natriuretic peptide. Ren Fail, 17(2), 117-23, 1995

Johnson, D H, Paul, D M, Hande, K R, DeVore, R F. Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial--LUN-46. Semin Oncol, 22(4 Suppl 9), 30-3, 1995

Thompson, D S, Hainsworth, J D, Hande, K R, Holzmer, M, Greco, F A. Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study. Cancer, 73(11), 2824-31, 1994

Anthony L, Johnson D, Hande K, Winn S, Krozley M, and Oates J. Somatostatin analogue Phase I trials in neuroendocrine tumors. Acta Oncologica 32:217-223, 1993.

Hande KR and Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin?s lymphoma. Am J.Med 94:133-130, 1993.

Hande KR and Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin?s lymphoma. Am J.Med 94:133-130, 1993.

Hande KR, Krozley MG, Greco FA, et al. Bioavailability of low dose oral etoposide. J Clin Oncol 11:374-377, 1993.

Hande KR. Pharmacologic-based dosing of carboplatinum: A better method. J Clin Oncol 11:2295-2296, 1993.

Thompson DS, Hainsworth JD, Hande KR, et al. Prolonged administration of low-dose infusional etoposide in patients with etoposide-sensitive neoplasms: A phase I/II study. J Clin Oncol 11:1322-1328, 1993.

Hande, K R, Garrow, G C. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med, 94(2), 133-9, 1993

Hande, K R, Krozely, M G, Greco, F A, Hainsworth, J D, Johnson, D H. Bioavailability of low-dose oral etoposide. J Clin Oncol, 11(2), 374-7, 1993

Thompson, D S, Hainsworth, J D, Hande, K R, Holzmer, M C, Greco, F A. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J Clin Oncol, 11(7), 1322-8, 1993

Hande KR. Antitumor antibiotics, epipodophyllotoxins and vinca alkaloids. Curr Opin Oncol 4:1080 1088, 1992.

Hande KR. Etoposide Pharmacology. Sem Oncol 19:(suppl) 3 9, 1992.

Ormond PM, Basinger MA, Jones MM, and Hande KR. Association between increased atrial naturetic peptide and reduced cisplatin nephrotoxicity in rats. J Pharm Exp Ther 262:246 251, 1992.

Waites TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, and Greco FA. Prolonged administration of oral etoposide in non small cell lung cancer: A Phase II trial. J Clin Oncol 10:292 296, 1992.

Greco, F A, Murphy, P B, Hainsworth, J D, Hande, K R, Johnson, D H. Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer. Oncology, 49 Suppl 1, 34-8; discussion 39, 1992

Hande, K R. Antitumor antibiotics, epipodophyllotoxins, and vinca alkaloids. Curr Opin Oncol, 4(6), 1080-8, 1992

Hande, K R. Etoposide pharmacology. Semin Oncol, 19(6 Suppl 13), 3-9, 1992

Johnson, D H, DeVore, R, Greco, F A, Walls, J, Thomas, M, Hande, K R, Hainsworth, J D. Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial. Semin Oncol, 19(1 Suppl 2), 50-6, 1992

Johnson, D H, Hainsworth, J D, DeVore, R, Hande, K R, Greco, F A. Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt trial. Oncology, 49 Suppl 1, 57-61; discussion 61-2, 1992

Johnson, D H, Hainsworth, J D, Hande, K R, Greco, F A. Combination chemotherapy with oral etoposide. Semin Oncol, 19(6 Suppl 14), 19-24, 1992

Murphy, P B, Hainsworth, J D, Greco, F A, Hande, K R, DeVore, R F, Johnson, D H. A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer. Cancer, 69(2), 370-5, 1992

Ormond, P M, Basinger, M A, Jones, M M, Hande, K R. Association between increased atrial natriuretic peptide and reduced cisplatin nephrotoxicity in rats. J Pharmacol Exp Ther, 262(1), 246-51, 1992

Waits, T M, Johnson, D H, Hainsworth, J D, Hande, K R, Thomas, M, Greco, F A. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. J Clin Oncol, 10(2), 292-6, 1992

Hande KR. Drug monitoring in cancer therapy. J Natl Cancer Inst 83:1523 1524, 1991.

Johnson, D H, Hainsworth, J D, Hande, K R, Greco, F A. Current status of etoposide in the management of small cell lung cancer. Cancer, 67(1 Suppl), 231-44, 1991

Johnson, D H, Strupp, J, Greco, F A, Stewart, J, Merrill, W, Malcolm, A, Hande, K R, Hainsworth, J D. Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer. Cancer, 68(6), 1216-20, 1991

Anthony LB, Long QC, Struck SF and Hande KR. The effect of cimetidine on cyclophosphamide metabolism in rabbits. Cancer Chemother Pharmacol 27:125 130, 1990.

Hande, KR, Kuttesch, J, Hamilton, M, Satterlee, et al. Kinetics of N [(4 Chlorophenyl) amino] carbonyl 2,3, dihydro lH indene sulfonamide in man. Cancer Research 51:3910 3914, 1990.

Hande, KR, Wolff, SN, Greco, FA, Hainsworth, JD, Reed, G, and Johnson, DH. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 8:1101 1107, 1990.

Johnson, DH, Greco, FA, Strupp, J, Hande KR, and Hainsworth, JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: A Phase II trial. J Clin Oncol 8:1613 1617, 1990.

Anthony, L B, Long, Q C, Struck, R F, Hande, K R. The effect of cimetidine on cyclophosphamide metabolism in rabbits. Cancer Chemother Pharmacol, 27(2), 125-30, 1990

Hande, K R, Kuttesch, J, Hamilton, M, Satterlee, W, Jackson, L, Grindey, G, Hainsworth, J D. Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans. Cancer Res, 50(13), 3910-4, 1990

Hande, K R, Wolff, S N, Greco, F A, Hainsworth, J D, Reed, G, Johnson, D H. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol, 8(6), 1101-7, 1990

Johnson, D H, Greco, F A, Strupp, J, Hande, K R, Hainsworth, J D. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol, 8(10), 1613-7, 1990

Hainsworth, JD, Hande, KR, Satterlee, WG, Kuttesch, et al. Phase I clinical study of N-[(4-Chlorophenyl) amino] carbony1 2,3-dihydro-1H indene-5-sulfonamide (LY186641). Cancer Res 49:5217-5220, 1989.

Mangum, M, Greco, FA, Hainsworth, Hande, KR and Johnson, DH. Combined small-cell and non-small cell lung cancer. J. Clin Oncol, 7:607-612, 1989

Hainsworth, J D, Hande, K R, Satterlee, W G, Kuttesch, J, Johnson, D H, Grindey, G, Jackson, L E, Greco, F A. Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641). Cancer Res, 49(18), 5217-20, 1989

Hainsworth, J D, Johnson, D H, Hande, K R, Greco, F A. Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens. Am J Clin Oncol, 12(4), 345-9, 1989

Mangum, M D, Greco, F A, Hainsworth, J D, Hande, K R, Johnson, D H. Combined small-cell and non-small-cell lung cancer. J Clin Oncol, 7(5), 607-12, 1989

Dessypris, E.N., Brenner, D.E., Baer, M.R., and Hande, K.R. Uptake and intracellular distribution of doxorubicin metabolites in B-lymphocytes of chronic lymphocytic leukemia. Cancer Res, 48:503-506, 1988.

Hande, K.R., Anthony, L.B., Hamilton, R., Bennett, R., Sweetman, B. and Branch, R. Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit. Cancer Res 48:1829-1834, 1988.

Hande, KR, Bennett, R, Hamilton, R, Grote, T, and Branch, R. Metabolism and excretion of etoposide in isolated perfused rat liver models. Cancer Res, 48:5692-5695, 1988.

List, AF, Greer, JP, Cousar, JC, Stein RS, Johnson DH, Reynolds VH, Greco, FA, Flexner, JM and Hande, KR. Non-Hodgkin's lymphoma of the gastrointestinal tract: An analysis of clinical and pathological features affecting outcome. J. Clin Oncol, 6:1125-1133, 1988.

List, A F, Greer, J P, Cousar, J C, Stein, R S, Johnson, D H, Reynolds, V H, Greco, F A, Flexner, J M, Hande, K R. Non-Hodgkin's lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome. J Clin Oncol, 6(7), 1125-33, 1988

Brenner, D.E., Anthony, L.B., Halter, S., Harris, N.L., and Hande, K.R. Effects of ethyl alcohol-induced sublethal hepatic damage upon doxorubicin metabolism and toxicity in the rabbit. Cancer Res 47:3259-3265, 1987.

Wolff, S.N., Grosh, W.W., Prater, K., and Hande, K.R. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Cancer Chemother Pharmacol 19:246-249, 1987.

Johnson, D H, Porter, L L, List, A F, Hande, K R, Hainsworth, J D, Greco, F A. Acute nonlymphocytic leukemia after treatment of small cell lung cancer. Am J Med, 81(6), 962-8, 1986


Postdoctoral Position Available
N/A

Postdoctoral Position Details
N/A

Updated Date
06/03/2003